ALC vs AZN
Alcon Inc vs AstraZeneca PLC — AI-powered side-by-side comparison
VS
AZN
AstraZeneca PLC
56
Watch
| Metric | ALC | AZN |
|---|
| AI Score |
68
|
56
|
| Price |
$75.39
|
$158.74
|
| P/E Ratio |
45.39×
|
23.81×
|
| ROE |
4.4%
|
21.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
79.3%
|
| Debt / Equity |
0.24×
|
0.64×
|
| Dividend Yield |
0.5%
|
1.3%
|
| RSI (14) |
73.4
|
33.8
|
| Beta |
0.703
|
0.211
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus AZN.
ALC leads by 12 points.
ALC scores 68/100 (Buy) versus AZN at 56/100 (Watch).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
AZN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.94 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 21.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.9% YoY — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical